SUMMARY
The development of antimicrobial resistance involves the rise of heterogeneity in populations of
microbes by uncertain mechanisms. This Unit is focused on the understanding the rise of cell-
states that we call enablers that give rise to treatment failure. Identifying these cell states
requires the development, sharing, implementation support, and analytical training of a broad
suite of genomics and bioinformatics methods for each scientific project. The key function of this
Core is to integrate methods, data, and support team members with their analysis goals. This
Genomics and Bioinformatics core commits to provide this support and analytical leadership by
establishing rigorous workflows for a wide range of nucleic acid library preparations. In addition,
we will develop and share a range of innovative bioinformatic analyses methods for assembly,
quantitative read-mapping, community profiling, and portable bacterial genome nomenclature.
Most importantly for the broader impact of this project, we will enable iterative, reproducible
inquiry of ‘omics data with bioinformatics training for trainees, staff, and collaborators throughout
the team.
In Aim 1, we develop and provide methods to analyze genome fragments or amplicons, including
gDNA sequencing, barcode sequencing, Tn-Seq, droplet-TnSeq (dTnseq), Deplete-seq (called
Enabler-seq here) and CRISPRi/Tn-seq. We will also continue development and economization
of RNAseq methods such as RNAtag-Seq, dual-host-microbe RNA-seq (dRNA-Seq), 3’-end map-
sequencing (3pMap / Term-Seq), and will develop the use of direct RNA sequencing to identify
transcript modifications or isoforms that drive enabler types. In Aim 2, we develop and support
implementation of a variety of analysis methods to turn these ‘omics data into knowledge,
including an innovative pipeline called Aerobio that addresses the challenge of integrating multiple
data and analysis streams and new inference platforms like LOLIPoP and BFClust. In Aim 3 we
focus on democratizing data exploration throughout the team and ultimately for the broader
research community by offering training on portable methods. These efforts include a new, flexible
ortholog identification tool with a graphical interface (OrthoPathDB) built upon our published
ShinyOmics, shared resources for distributed installation, and regular training in genomic DNA
analysis, RNAseq, amplicon sequencing, and host immunity - microbe interactions. In summary,
this Core will consistently generate high-quality data and provide unfettered access to both wet-
bench and bioinformatic methodology, as well as their workflow status, via open sharing and
training.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAntibiotic TherapyAntimicrobial ResistanceBacterial GenomeBar CodesBioinformaticsCRISPR interferenceCellsCommunitiesCustomDNA analysisDNA methylation profilingDataDatabasesDemocracyDepositionDevelopmentEducational process of instructingEducational workshopFailureGenesGenomeGenomic DNAGenomicsGenotypeGoalsGuppyHeterogeneityHigh-Throughput Nucleotide SequencingImmunityInstitutionLeadershipLibrariesMapsMediatingMetagenomicsMethodologyMethodsMicrobeModificationNomenclatureNucleic AcidsOrthologous GenePerformancePopulationPreparationProtein IsoformsPublishingRNAReproducibilityResearchResearch PersonnelResource SharingResourcesSalmonShotgunsStreamTrainingTranscriptTreatment FailureUniversitiesVisualizationautomated analysiscomparative genomicsdata explorationdata sharingdata to knowledgedeep sequencingdroplet sequencingflexibilityforestgraphical user interfacehost-microbe interactionsinnovationmembermethylomenanoporepathogenportabilitypublic databasescreeningtooltranscriptome sequencingtransposon sequencingweb app
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
076593722
UEI
Z1L9F1MM1RY3
Project Start Date
12-September-2022
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$566,147
Direct Costs
$399,487
Indirect Costs
$166,660
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$566,147
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7U19AI158076-03 8510
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7U19AI158076-03 8510
Patents
No Patents information available for 7U19AI158076-03 8510
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7U19AI158076-03 8510
Clinical Studies
No Clinical Studies information available for 7U19AI158076-03 8510
News and More
Related News Releases
No news release information available for 7U19AI158076-03 8510
History
No Historical information available for 7U19AI158076-03 8510
Similar Projects
No Similar Projects information available for 7U19AI158076-03 8510